CdM | Faes Farma (FAES) profits have suffered in the first nine months of 2025. According to the company’s report to the Spanish National Securities Market Commission (CNMV), net profits between January and September amounted to €73.56 million, 7.9% less than the €79.84 million recorded in the same period in 2024.
EBITDA stood at £106.5 million until September, down 2.7%. However, this figure was at the high end of the company’s profit guidance (a drop of between 6% and 9%).
In turn, personnel expenses increased by 10.3% to €89.44 million, and other operating expenses rose by 31.3% to €104.62 million. According to Faes, this increase in expenses was in line with the priorities of its 2025-2030 Strategic Plan, as well as with expenses arising from M&A (mergers and acquisitions) operations.
Revenue amounted to £453.99 million, representing an increase of 15.5% compared to the cumulative turnover up to September last year. Specifically, revenue from the Pharmaceuticals division rose by more than 13% in the first nine months of the year to €399.5 million, thanks to strong performance in the Latin American market (up 16%, €83.8 million) and licensing (up 17%).
In the rest of the world, revenues increased by 23% to €45.8 million, as ‘the effects of seasonal sales in this quarter, which will reverse into incremental revenues in the following quarters,’ were diluted.
Revenue from Faes’ three strategic molecules (bilastine, calcifediol and mesalazine) continues to grow ‘strongly’ after sales rose 15% in the period. Bilastine revenue improved by 11%, while calcifediol and mesalazine revenue increased by 15% and 59%, respectively.
On the other hand, revenues from FARM Faes, the Animal Nutrition and Health division, recorded a remarkable 48% increase, bringing sales to €57.8 million.
